We recently published a list of 10 Best Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are going ...

Medical diagnostics company Guardant Health has sued rival Natera in California federal court for allegedly stealing trade ...

Piper Sandler analyst David Westenberg raised the firm’s price target on Guardant Health (GH) to $50 from $34 following quarterly results. The ...

Here is how Guardant Health (GH) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.

In a report released today, David Westenberg from Piper Sandler maintained a Buy rating on Guardant Health (GH – Research Report), with a price ...

Guggenheim restated their buy rating on shares of Guardant Health (NASDAQ:GH – Free Report) in a report released on Monday ...

Guardant Health (NASDAQ:GH – Get Free Report) had its target price boosted by research analysts at The Goldman Sachs Group ...

The oncology testing specialist reported strong top-line growth, but also rising costs and ongoing net losses.

As of December 2024, Guardant held $840 million of cash and marketable securities. However, it burned through approximately $390 million in 2022, $345 million in 2023, and $275 million in 2024.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ...

Explore Guardant Health's Q4 2024 earnings report, highlighting record revenue, Shield's commercial milestones, and a strong 2025 growth outlook.